...acquisition of Hapto for 30.9 million shares (see BioCentury, Dec. 19, 2005). The deal values Hapto...
...based on ORTC's close of $0.32 on April 17, the day the deal was completed. Hapto Biotech Inc....

...ORTN), New York, N.Y. Business: Gene/Cell therapy ORTN signed a letter of intent to acquire Hapto...
...on ORTN's close of $0.18 on Dec. 14, the day before the deal was announced. Hapto...
...to purchase ORTN stock at $0.35. The deal is expected to close within 45 days. Hapto...

...ulcers. OrCel is FDA approved to treat epidermolysis bullosa and donor sites in burn patients. Hapto Biotech Inc....

...wound healing and tissue regeneration. The compounds were identified under a 2002 research deal using Hapto's...
...bilayered cellular matrix technology. The companies plan to out-license resulting products for co-development and commercialization. Hapto Biotech Inc....

...wound healing and tissue regeneration. The compounds were identified under a 2002 research deal using Hapto's...

...matrix technology with Hapto's Haptide synthetic peptide technology, which enhances cell attachment and facilitates growth. Hapto...